| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 11/22/2023 | 262.9% | HC Wainwright & Co. | → $4.5 | Reiterates | Buy → Buy |
| 08/21/2023 | 262.9% | HC Wainwright & Co. | → $4.5 | Reiterates | Buy → Buy |
| 05/05/2023 | 303.23% | RBC Capital | $6 → $5 | Maintains | Outperform |
| 03/24/2023 | 262.9% | HC Wainwright & Co. | → $4.5 | Reiterates | → Buy |
| 03/16/2023 | 303.23% | Wedbush | → $5 | Reiterates | → Outperform |
| 03/16/2023 | 383.87% | RBC Capital | → $6 | Reiterates | → Outperform |
| 01/06/2023 | 61.29% | Jefferies | $5 → $2 | Downgrades | Buy → Hold |
| 08/22/2022 | 262.9% | HC Wainwright & Co. | $14 → $4.5 | Maintains | Buy |
| 08/02/2022 | 101.61% | BMO Capital | $8 → $2.5 | Downgrades | Outperform → Market Perform |
| 08/02/2022 | — | BTIG | Downgrades | Buy → Neutral | |
| 05/11/2022 | 1029.03% | RBC Capital | $15 → $14 | Maintains | Outperform |
| 05/04/2022 | 1029.03% | HC Wainwright & Co. | → $14 | Initiates Coverage On | → Buy |
| 03/22/2022 | 867.74% | BMO Capital | $17 → $12 | Maintains | Outperform |
| 04/06/2021 | 1109.68% | RBC Capital | → $15 | Initiates Coverage On | → Outperform |
| 03/08/2021 | — | Cowen & Co. | Initiates Coverage On | → Outperform | |
| 03/08/2021 | 1512.9% | Jefferies | → $20 | Initiates Coverage On | → Buy |
| 03/08/2021 | 1190.32% | BMO Capital | → $16 | Initiates Coverage On | → Outperform |
| 03/08/2021 | 1512.9% | Wedbush | → $20 | Initiates Coverage On | → Outperform |
| 03/08/2021 | 1190.32% | BTIG | → $16 | Initiates Coverage On | → Buy |
What is the target price for Nuvation Bio (NUVB)?
The latest price target for Nuvation Bio (NYSE: NUVB) was reported by HC Wainwright & Co. on November 22, 2023. The analyst firm set a price target for $4.50 expecting NUVB to rise to within 12 months (a possible 262.90% upside). 7 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Nuvation Bio (NUVB)?
The latest analyst rating for Nuvation Bio (NYSE: NUVB) was provided by HC Wainwright & Co., and Nuvation Bio reiterated their buy rating.
When is the next analyst rating going to be posted or updated for Nuvation Bio (NUVB)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Nuvation Bio, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Nuvation Bio was filed on November 22, 2023 so you should expect the next rating to be made available sometime around November 22, 2024.
Is the Analyst Rating Nuvation Bio (NUVB) correct?
While ratings are subjective and will change, the latest Nuvation Bio (NUVB) rating was a reiterated with a price target of $0.00 to $4.50. The current price Nuvation Bio (NUVB) is trading at is $1.24, which is within the analyst's predicted range.